Reduced heterochromatin protein 1-beta (HP1β) expression is correlated with increased invasive activity in human melanoma cells

Anticancer Research

Volumn 26, Issue 6 B, 2006, Pages 4349-4356

  Nishimura, Keisuke ^a   Hirokawa, Yoshifumi S ^a   Mizutani, Hitoshi ^a   Shiraishi, Taizo ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

V600EB RAF mutation; Heterochromatin protein 1 beta (HP1 ); Invasion; Malignant melanoma; Metastasis; Microphthalmia associated transcription factor (MITF); RNAi

Indexed keywords

B RAF KINASE; HETEROCHROMATIN PROTEIN 1; HETEROCHROMATIN PROTEIN 1 ALPHA; HETEROCHROMATIN PROTEIN 1 BETA; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BASE SEQUENCE; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA PRIMERS; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; RNA INTERFERENCE; RNA, MESSENGER;

EID: 33845945627     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Brown KE, Baxter J, Graf D, Merkenschlager M and Fisher AG: Dynamic repositioning of genes in the nucleus of lymphocytes preparing for cell division. Mol Cell 3: 207-217, 1999.
2. Francastel C, Walters MC, Groudine M and Martin DI: A functional enhancer suppresses silencing of a transgene and prevents its localization close to centrometric heterochromatin. Cell 99: 259-269, 1999.
3. Henikoff S: Position-effect variegation after 60 years. Trends Genet 6: 422-426, 1990.
4. Ayyanathan K, Lechner MS, Bell P, Maul GG, Schultz DC, Yamada Y, Tanaka K, Torigoe K and Rauscher FJ 3rd: Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation. Genes Dev 17: 1855-1869, 2003.
5. Eissenberg JC, James TC, Foster-Hartnett DM, Hartnett T, Ngan V and Elgin SC: Mutation in a heterochromatin-specific chromosomal protein is associated with suppression of position-effect variegation in Drosophila melanogaster. Proc Natl Acad Sci USA 87: 9923-9927, 1990.
6. Eissenberg JC, Morris GD, Reuter G and Hartnett T: The heterochromatin-associated protein HP-1 is an essential protein in Drosophila with dosage-dependent effects on position-effect variegation. Genetics 131: 345-352, 1992.
7. Lechner MS, Begg GE, Speicher DW and Rauscher FJ 3rd: Molecular determinants for targeting heterochromatin protein 1-mediated gene silencing: direct chromoshadow domain-KAP-1 corepressor interaction is essential. Mol Cell Biol 20: 6449-6465, 2000.
8. Ryan RF, Schultz DC, Ayyanathan K, Singh PB, Friedman JR, Fredericks WJ and Rauscher FJ 3rd: KAP-1 corepressor protein interacts and co-localizes with heterochromatic and euchromatic HP1 proteins: a potential role for Kruppel-associated box-zinc finger proteins in heterochromatin-mediated gene silencing. Mol Cell Biol 19: 4366-4378, 1999.
9. Li Y, Kirschmann DA and Wallrath LL: Does heterochromatin protein 1 always follow code? Proc Natl Acad Sci USA 99: 16462-16469, 2002.
10. Maison C and Almouzni G: HP1 and the dynamics of heterochromatin maintenance. Nat Rev Mol Cell Biol 5: 296-304, 2004.
11. Muchardt C, Guilleme M, Seeler JS, Trouche D, Dejean A and Yaniv M: Coordinated methyl and RNA binding is required for heterochromatin localization of mammalian HP1alpha. EMBO Rep 3: 975-981, 2002.
12. Meehan RR, Kao CF and Pennings S: HP1 binding to native chromatin in vitro is determined by the hinge region and not by the chromodomain. EMBO J 22: 3164-3174, 2003.
13. Sugimoto K, Yamada T, Muro Y and Himeno M: Human homolog of Drosophila heterochromatin-associated protein 1 (HP1) is a DNA-binding protein which possesses a DNA-binding motif with weak similarity to that of human centromere protein C (CENP-C). J Biochem (Tokyo) 120: 153-159, 1996.
14. Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC and Kouzarides T: Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410: 120-124, 2001.
15. Lachner M, O'Carroll D, Rea S, Mechtler K and Jenuwein T: Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410: 116-120, 2001.
16. Nakayama J, Rice JC, Strahl BD, Allis CD and Grewal SI: Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 292: 110-113, 2001.
17. Singh PB, Miller JR, Pearce J, Kothary R, Burton RD, Paro R, James TC and Gaunt SJ: A sequence motif found in a Drosophila heterochromatin protein is conserved in animals and plants. Nucleic Acids Res 19: 789-794, 1991.
18. Mine E, Courvalin JC and Buendia B: HP1gamma associates with euchromatin and heterochromatin in mammalian nuclei and chromosomes. Cytogenet Cell Genet 90: 279-284, 2000.
19. Nielsen AL, Oulad-Abdelghani M, Ortiz JA, Remboutsika E, Chambon P and Losson R: Heterochromatin formation in mammalian cells: interaction between histones and HP1 proteins. Mol Cell 7: 729-739, 2001.
20. Le Douarin B, Nielsen AL, Garnier JM, Ichinose H, Jeanmougin F, Losson R and Chambon P: A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. EMBO J 15: 6701-6715, 1996.
21. Verschure PJ, van der Kraan I, de Leeuw W, van der Vlag J, Carpenter AE, Belmont AS and van Driel R: In vivo HP1 targeting causes large-scale chromatin condensation and enhanced histone lysine methylation. Mol Cell Biol 25: 4552-4564, 2005.
22. Kirschmann DA, Lininger RA, Gardner LM, Seftor EA, Odero VA, Ainsztein AM, Earnshaw WC, Wallrath LL and Hendrix MJ: Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer. Cancer Res 60: 3359-3363, 2000.
23. van Elsas A, Zerp SF, van der Flier S, Kruse KM, Aarnoudse C, Hayward NK, Ruiter DJ and Schrier PI: Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 149: 883-893, 1996.
24. Tsao H, Zhang X, Fowlkes K and Haluska FG: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 60: 1800-1804, 2000.
25. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ and Marais R: V599EB-RAF is an oncogene in melanocytes. Cancer Res 64: 2338-2342, 2004.
26. Wellbrock C and Marais R: Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 170: 703-708, 2005.
27. Widlund HR and Fisher DE: Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 22: 3035-3041, 2003.
28. Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D and Das Gupta TK: Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 60: 5012-5016, 2000.
29. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
30. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J et al: High frequency of BRAF mutations in naevi. Nat Genet 33: 19-20, 2003.
31. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE and Herlyn M: Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759, 2003.
32. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z and Aaronson SA: BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63: 3883-3885, 2003.
33. Bradbury J: RNA interference: new drugs on the horizon. Drug Discov Today 10: 1266-1267, 2005.
34. Hammond SM: Dicing and slicing - the core machinery of the RNA interference pathway. FEBS Lett 579: 5822-5829, 2005.
35. Lu PY, Xie F and Woodle MC: In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 54: 117-142, 2005.
36. Sandy P, Ventura A and Jacks T: Mammalian RNAi: a practical guide. Biotechniques 59: 215-224, 2005.
37. Hwang KK and Worman HJ: Gene regulation by human orthologs of Drosophila heterochromatin protein 1. Biochem Biophys Res Commun 293: 1217-1222, 2002.
38. Sharma GG, Hwang KK, Pandita RK, Gupta A, Dhar S, Parenteau J, Agarwal M, Worman HJ, Wellinger RJ and Pandita TK: Human heterochromatin protein 1 isoforms HP1(Hsalpha) and HP1(Hsbeta) interfere with hTERT-telomere interactions and correlate with changes in cell growth and response to ionizing radiation. Mol Cell Biol 23: 8363-8376, 2003.
39. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis DP and Seshagiri S: Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66: 999-1006, 2006.
40. Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B, Schulte KW Ruzicka T and Reifenberger G: Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 109: 377-384, 2004.
41. Papp T, Schipper H, Kumar K, Schiffmann D and Zimmermann R: Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi. Melanoma Res 15: 401-407, 2005.
42. Uribe P, Andrade L and Gonzalez S: Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol 126: 161-166, 2006.
43. Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K, Kambara T, MacPhee DG, Young J, Leggett BA, Jass JR, Tanaka N and Matsubara N: Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 222: 4584-4594, 2004.
44. Pruitt K, Ulku AS, Frantz K, Rojas RJ, Muniz-Medina VM, Rangnekar VM, Der CJ and Shields JM: Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem 280: 23363-23370, 2005.
45. Hakimi MA, Bochar DA, Chenoweth J, Lane WS, Mandel G and Shiekhattar R: A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc Natl Acad Sci USA 99: 7420-7425, 2002.
46. Iwase S, Januma A, Miyamoto K, Shono N, Honda A, Yanagisawa J and Baba T: Characterization of BHC80 in BRAF-HDAC complex, involved in neuron-specific gene repression. Biochem Biophys Res Commun 322: 601-608, 2004.
47. Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino MC, Travail S and McCubrey JA: Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 4: 1382-1384, 2005.